Blockade of the CCL2-CCR2 axis strongly reduces the incidence of tumor by inhibiting TAMs recruitment and enhancing the anti-tumor efficacy of CD8 + T cells in the TME [22, 23]. The gene discussed is CCR2; the disease is neoplasm.